Print

Sunshine Biopharma, Inc. Completes Another IND-Enabling Study: Adva-27a is Found to be Effective Against Multidrug Resistant Uterine Cancer Cells  
12/10/2012 9:21:08 AM

MONTREAL--(Marketwire - December 10, 2012) - Sunshine Biopharma Inc. (OTCQB: SBFM), a pharmaceutical company focused on the research, development and commercialization of drugs for the treatment of various forms of cancer, today announced that it has completed a new IND-Enabling study in which Adva-27a, the Company's flagship oncology drug candidate, was found to be effective at killing Multidrug Resistant Uterine Cancer Cells in vitro. The study was carried out in MES-SA/Dx5, a Uterine Sarcoma cell line that has become multidrug resistant through the use of a commonly administered chemotherapy drug, Doxorubicin. Adva-27a was able to kill these cells with an IC50 of less than 8 micromolar, a very pharmacologically favorable drug concentration. Sunshine Biopharma had previously reported that Adva-27a is also capable of effectively killing Multidrug Resistant Breast Cancer Cells (MCF-7/MDR) and Small-Cell Lung Cancer Cells (H69AR) in vitro.

"This brings to three the total number of Multidrug Resistant Cancer types that Adva-27a can destroy. Other chemotherapy drugs are completely ineffective against these cancers," said Dr. Steve N. Slilaty, CEO of Sunshine Biopharma. "This confirms the general effectiveness of Adva-27a against Multidrug Resistant Cancer," he added.

About Sunshine Biopharma Inc.
Sunshine Biopharma is an early stage pharmaceutical company focused on the research, development and commercialization of drugs for the treatment of various forms of cancer. Sunshine Biopharma recently announced that it has initiated IND-Enabling studies for its lead antitumor compound, Adva-27a.

Safe Harbor Forward-Looking Statements
To the extent that statements in this press release are not strictly historical, including statements as to revenue projections, business strategy, outlook, objectives, future milestones, plans, intentions, goals, future financial conditions, future collaboration agreements, the success of the Company's development, events conditioned on stockholder or other approval, or otherwise as to future events, such statements are forward-looking, and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The forward-looking statements contained in this release are subject to certain risks and uncertainties that could cause actual results to differ materially from the statements made.


For Additional Information Contact:
Camille Sebaaly
CFO
Sunshine Biopharma Inc.
Direct Line: 514-814-0464
camille.sebaaly@sunshinebiopharma.com
www.sunshinebiopharma.com


//-->